Everything below concerns animal model. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Last reviewed on 2025-08-18. Where a claim depends on a specific study, the study is described rather than over-claimed.
Published studies on BPC-157 are dominated by animal models. Commonly used endpoints include healing of surgically induced lesions in the stomach, tendon-to-bone attachment after transection, and recovery from experimentally induced vascular or intestinal damage. Many of these reports come from a small number of research groups, and the peptide is often described as acting across a wide range of tissue types. That breadth is itself a point of discussion, since one molecule influencing many unrelated systems is unusual.
Human data are far more limited than animal data. A small number of clinical reports exist, generally with few participants and without the randomization or blinding expected in later-phase trials. No large, independently replicated human trial has appeared in the indexed peer-reviewed literature. Statements about effects in people therefore rest on extrapolation from animal work rather than on direct evidence, and the strength of that extrapolation remains an open question rather than a settled matter.
Proposed mechanisms include interaction with the nitric oxide system, modulation of growth factor signaling, and effects on blood vessel formation. None of these has been established as the primary mode of action, and some proposed pathways rest on indirect measurements. Whether the reported effects depend on a specific receptor has not been determined. Stability in gastric acid, unusual for a peptide of this size, is also reported in animal work, but the reason for it is not firmly established.
A freeze-dried sample is generally the most stable form and is commonly held at minus twenty degrees Celsius or lower for long-term keeping, with brief transfers at room temperature. The solid is hygroscopic, so vials are warmed to ambient temperature before opening to prevent condensation from degrading the contents. Light exposure and repeated temperature cycling are both avoided in routine handling. Storage over a desiccant is a common laboratory practice that limits moisture uptake during repeated access.
Once dissolved, the material is considerably less stable than the dry solid. Aqueous solutions are usually kept cold and used within a short window, and neutral or mildly acidic buffers are preferred over strongly alkaline conditions. Freeze-thaw cycles promote aggregation and loss of material to container surfaces, so dividing a batch into single-use aliquots is standard. Adsorption to plastic and glass can lower the measured concentration, meaning solution strength may need rechecking before an experiment.
Identity and purity are established with complementary methods rather than one test. Reverse-phase high-performance liquid chromatography separates the main peak from deletion sequences and oxidized variants, and its area percentage is the usual purity figure. Mass spectrometry confirms the expected molecular mass and can flag truncations or modifications that chromatography alone might miss. Amino acid analysis and peptide mapping add sequence-level confirmation, while residual counter-ion and water content are measured separately.
| Property | Value | Notes |
|---|---|---|
| Study species | Rodents, mainly rats | Most reports use surgically induced injury models |
| Typical administration route | Subcutaneous or intraperitoneal injection | Routes differ between reports, which complicates comparison |
| Human trial evidence | Limited, small-scale reports | No large randomized trial in indexed journals |
| Reported outcome categories | Mucosal healing, tendon repair, vascular recovery | Endpoints are not standardized across studies |
| Mechanism status | Not established | Proposed pathways lack direct confirmation |
BPC-157 is a synthetic peptide composed of fifteen amino acid residues, with the sequence Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val. Its name derives from body protection compound, a term used for a protein fraction identified in human gastric juice. Researchers in Zagreb first reported the pentadecapeptide in the early 1990s and described it as a stable fragment of that larger protein. The compound is also catalogued as PL 14736 and, in some commercial contexts, as bepecin. Its molecular formula is C62H98N16O22 and its monoisotopic mass is approximately 1419 daltons.
Most published work on BPC-157 consists of preclinical studies, including rodent models of tissue injury, gastrointestinal lesions, and vascular or tendon damage, together with in vitro cell assays. Reviews frequently note that the mechanisms proposed in these papers remain incompletely characterised and that findings have not been confirmed in large randomised human trials. The compound is widely sold as a research chemical rather than a licensed medicine, and labels commonly carry a statement that it is not for human use. Whether any of the reported animal effects translate to humans is an open question rather than an established result.
Most published studies examine BPC-157 in animal models rather than in humans. Common subjects include rats and mice, and researchers often use models of tissue injury, surgery, or induced inflammation. Reported endpoints include healing rates, blood vessel formation, and markers of tissue repair. These designs provide controlled comparisons, but findings in animals do not automatically transfer to people. Human clinical data remain limited and are frequently described as preliminary.
Doses in the literature are usually expressed in micrograms or nanograms per kilogram of body weight. Investigators have administered the peptide by several routes, including injection and oral delivery, depending on the question asked. Route and dose vary widely across studies, which complicates direct comparison of results. Many papers report effects at low doses, but the absence of a standardized protocol limits generalization. Reporting practice differs between research groups.
=== Available forms === Tiagabine is available in the form of 2, 4, 5, 10, 12, 15, and 16 mg oral tablets. The drug is taken 1 to 4 times per day due to its short elimination half-life. A sustained-release formulation would be advantageous but has not been developed or marketed.
federal government got involved, and thereby laid the foundation for the company's success many years later. The risk of waiving patents for COVID-19 vaccines is that it sets a precedent which may discourage the private sector from future investments in vaccines and other lifesaving technologies, and in turn, future technologies not yet developed will never come to market when the public sector fails to pick up the slack. As one financial analyst explained: "It would be intensively counterproductive, in the extreme, because what it would say to the industry is: 'Don't work on anything that we really care about, because if you do, we're just going to take it away from you.'" The "most depressing" worst-case outcome is that pharmaceutical firms give up on saving lives and focus on inventing quality of life treatments which are more profitable and less likely to be expropriated; the most notorious examples of such treatments are Pfizer's Viagra and Allergan's Botox. The "threat of losing developers is real" in the vaccine sector, which had withered away to only a handful of companies by the turn of the 21st century and by 2021 had only recently begun to grow again. However, Peter Bach has argued that whether this risk might be worth it deserves to be frankly debated: "If this action allows for more access and more people to have their lives saved today in 2021 and the consequence is down the road we may not have some new gene therapy for 100 kids, then that's the trade-off worth discussing".
== Further reading == ABARE (2000). National Plantation Inventory, March, 2000. 4p. Anon. (1997). Timber markets, home and away: Australian growers capitalising on international demand. Pie, Newsletter of Australia's International and National Primary Industries and Energy (PIE) R&D Organisations. Volume 7 (Summer Issue): p14. Avramidis et al. (2023). Basics of wood drying. link: [1] In: Springer Handbook of Wood Science and Technology Bootle, K.R. (1994). Wood in Australia: Types, Properties and Uses. McGraw-Hill Book Company, Sydney. 443p. Desch, H.E. and Dinwoodie, J.M. (1996). Timber: Structure, Properties, Conversion and Use. 7th ed. Macmillan Press Ltd., London. 306p. Doe, P.D., Oliver, A.R. and Booker, J.D. (1994). A Non-Linear Strain and Moisture Content Model of Variable Hardwood Drying Schedules. Proc. 4th IUFRO International Wood Drying Conference, Rotorua, New Zealand. 203-210pp. Haque, M.N. (1997). The Chemical Modification of Wood with Acetic Anhydride. MSc Dissertation. The University of Wales, Bangor, UK. 99p. Hoadley, R. Bruce (2000). Understanding Wood: A Craftsman's Guide to Wood Technology (2nd. ed.). Taunton Press. ISBN 1-56158-358-8. Innes, T. (1996). Improving Seasoned Hardwood Timber Quality with Particular Reference to Collapse. PhD Thesis. University of Tasmania, Australia. 172p. Keey, R.B., Langrish, T.A.G. and Walker, J.C.F. (2000). Kiln-Drying of Lumber. Springer, Berlin. 326p. Kollmann, F.F.P. and Cote, W.A.J. (1968). Principles of Wood Science and Technology. I. Solid Wood. Springer-Verlag, New York. 592p. Kumar, S. (1994).
Sources: en.wikipedia.org
In 1977 an animated musical television film of The Hobbit was made by Rankin-Bass, and in 1980 they produced the animated musical television film The Return of the King, which covered some of the portions of The Lord of the Rings that Bakshi was unable to complete. From 2001 to 2003 New Line Cinema released The Lord of the Rings as a trilogy of live-action films that were filmed in New Zealand and directed by Peter Jackson. The series was successful, performing extremely well commercially and winning numerous Oscars. From 2012 to 2014 Warner Bros. and New Line Cinema released The Hobbit, a series of three films based on The Hobbit, with Peter Jackson serving as executive producer, director, and co-writer. In 2017 Amazon acquired the global television rights to The Lord of the Rings, for a series of new stories set before The Fellowship of the Ring.
By the 18th century, Cossack hosts in the Russian Empire occupied effective buffer zones on its borders. The expansionist ambitions of the Empire relied on ensuring Cossack loyalty, which caused tension given their traditional exercise of freedom, democracy, self-rule, and independence. Cossacks such as Stenka Razin, Kondraty Bulavin, Ivan Mazepa and Yemelyan Pugachev led major anti-imperial wars and revolutions in the Empire in order to abolish slavery and harsh bureaucracy, and to maintain independence. The Empire responded with executions and tortures, the destruction of the western part of the Don Cossack Host during the Bulavin Rebellion in 1707–1708, the destruction of Baturyn after Mazepa's rebellion in 1708, and the formal dissolution of the Lower Dnieper Zaporozhian Host after Pugachev's Rebellion in 1775. After the Pugachev rebellion, the Empire renamed the Yaik Host, its capital, the Yaik Cossacks, and the Cossack town of Zimoveyskaya in the Don region to try to encourage the Cossacks to forget the men and their uprisings. It also formally dissolved the Lower Dnieper Zaporozhian Cossack Host, and destroyed their fortress on the Dnieper (the Sich itself). This may in part have been due to the participation of some Zaporozhian and other Ukrainian exiles in Pugachev's rebellion. During his campaign, Pugachev issued manifestos calling for restoration of all borders and freedoms of both the Polish–Lithuanian Commonwealth and the Lower Dnieper (Nyzovyi in Ukrainian) Cossack Host under the joint protectorate of Russia and the Commonwealth.
== Function == GSTZ1 is predominantly found in liver cells; more specifically, it is localized in both the cytosol and the mitochondria. GSTZ1 is essentially known for catalyzing glutathione-dependent isomerization of maleylacetoacetate to fumarylacetoacetate, which is the second-to-last step in the vital phenylalanine and tyrosine degradation pathway. It is the only enzyme in the GST family that catalyses a significant process in intermediary metabolism and it ensures that this enzyme can be found in a variety of species from humans to bacteria. Another function of the GSTZ1 is that it is in control of the biotransformation of alpha-haloacids, like dichloroacetic acid (DCA), to glyoxylic acid. This prevents the buildup of DCA, which can lead to asymptomatic hepatotoxicity and a reversible peripheral neuropathy. Both functions for this enzyme requires the presence of glutathione (GSH) in order to work.
Sources: en.wikipedia.org
=== Hydrogel cross-linked with polyacrylamide === Marketed as Bulkamid, this material is a synthetic non-particulate hydrogel composed of water and cross-linked polyacrylamide (2.5%). The size of the molecules is large which makes it resistant to migration. Since it is a non particulate homogeneous hydrogel, it is thought to retain elasticity and does not lead to hard tissue fibrosis or cause other significant reaction in the surrounding tissues. It is non-resorbable and non allergenic. In plastic surgery it is marketed as Aquamid. In one publication where it was used for FI, intersphincteric injection site was used via the intersphincteric route. This material has not achieved widespread use.
== Anatomical location == Fibrosis can occur in many tissues within the body, typically as a result of inflammation or damage. Common sites of fibrosis include the lungs, liver, kidneys, brain, and heart:
=== On nuclear factor kappa B === Certain poloxamers such as P85 have been shown not only to be able to transport target genes to target cells, but also to increase gene expression. Certain poloxamers, such as P85 and L61, have also been shown to stimulate transcription of NF kappaB genes, although the mechanism by which this is achieved is currently unknown, bar that P85 has been shown to induce phosphorylation of the inhibitory kappa.
Sources: en.wikipedia.org
It is not authorized as a medicine in the United States or the European Union. Regulatory treatment varies by jurisdiction, and in several places it is handled as a research chemical. Therapeutic claims are not supported by large human trials.
Human evidence is sparse and comes from small reports rather than large trials. Sample sizes are generally too small to support firm conclusions. The published record does not contain an independently replicated randomized trial.
Several pathways have been proposed, including effects on nitric oxide signaling and vessel formation. Direct confirmation of a primary molecular target is lacking. Some findings rest on indirect measurements, which leaves the mechanism an open question.
Low temperature slows the chemical reactions, such as oxidation and hydrolysis, that break down a peptide chain. Water and oxygen are the main drivers of degradation, so a cold and dry environment extends usable life. Actual shelf life depends on the batch, the salt form, and the container.